DNMT1 and breast carcinoma: After treating the two breast cancer cell lines with SB431542, a TGFβ type I receptor inhibitor that specifically inhibits SMAD2 and SMAD3 phosphorylation [14,29,30], which leads to down regulation of DNMT1 and upregulation of CLDN6.